Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties
© Anguille et al; licensee BioMed Central Ltd. 2009
Received: 1 July 2009
Accepted: 18 December 2009
Published: 18 December 2009
Optimization of the current dendritic cell (DC) culture protocol in order to promote the therapeutic efficacy of DC-based immunotherapy is warranted. Alternative differentiation of monocyte-derived DCs using granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-15 has been propagated as an attractive strategy in that regard. The applicability of these so-called IL-15 DCs has not yet been firmly established. We therefore developed a novel pre-clinical approach for the generation of IL-15 DCs with potent immunostimulatory properties.
Human CD14+ monocytes were differentiated with GM-CSF and IL-15 into immature DCs. Monocyte-derived DCs, conventionally differentiated in the presence of GM-CSF and IL-4, served as control. Subsequent maturation of IL-15 DCs was induced using two clinical grade maturation protocols: (i) a classic combination of pro-inflammatory cytokines (tumor necrosis factor-α, IL-1β, IL-6, prostaglandin E2) and (ii) a Toll-like receptor (TLR)7/8 agonist-based cocktail (R-848, interferon-γ, TNF-α and prostaglandin E2). In addition, both short-term (2-3 days) and long-term (6-7 days) DC culture protocols were compared. The different DC populations were characterized with respect to their phenotypic profile, migratory properties, cytokine production and T cell stimulation capacity.
The use of a TLR7/8 agonist-based cocktail resulted in a more optimal maturation of IL-15 DCs, as reflected by the higher phenotypic expression of CD83 and costimulatory molecules (CD70, CD80, CD86). The functional superiority of TLR7/8-activated IL-15 DCs over conventionally matured IL-15 DCs was evidenced by their (i) higher migratory potential, (ii) advantageous cytokine secretion profile (interferon-γ, IL-12p70) and (iii) superior capacity to stimulate autologous, antigen-specific T cell responses after passive peptide pulsing. Aside from a less pronounced production of bioactive IL-12p70, short-term versus long-term culture of TLR7/8-activated IL-15 DCs resulted in a migratory profile and T cell stimulation capacity that was in favour of short-term DC culture. In addition, we demonstrate that mRNA electroporation serves as an efficient antigen loading strategy of IL-15 DCs.
Here we show that short-term cultured and TLR7/8-activated IL-15 DCs fulfill all pre-clinical prerequisites of immunostimulatory DCs. The results of the present study might pave the way for the implementation of IL-15 DCs in immunotherapy protocols.
Since their discovery by Steinman and Cohn in 1973, dendritic cells (DCs) have been recognized as the strategic orchestrators of the innate and adaptive immune system [1–3]. Although our knowledge of DC biology is still expanding, several concepts are yet well established [3, 4]. Immature DCs are known to be the vigilant sentinels of the human immune system; they relentlessly screen the environment for the presence of antigen and are highly capable of antigen uptake [4, 5]. Mature DCs are able to present the processed antigens via major histocompatibility complexes (MHC) to T cells after their migration to secondary lymphoid organs. This process of DC-mediated migration is regulated by multiple factors, but expression of the chemokine receptor CCR7 is recognized to play a pivotal role . In the lymph nodes, three signals are required for the formation of an optimal immunological synapse between DCs and T cells and for the induction of desired T helper type 1 (Th1) immune response: (1) recognition of MHC-presented antigens by T cell receptors, (2) delivery of costimulatory signals via the CD80/CD86-CD28 pathway, and (3) secretion of interleukin (IL)-12p70 by DCs after CD40/CD40 ligand signalling .
Since DCs are key regulators of the human immune system, their use under the form of a cellular vaccine is an attractive strategy for the treatment of cancer and infectious diseases . Since the results of the first clinical DC vaccine trial were published in 1996 , the field of DC-based immunotherapy has been increasingly translated into clinical practice, as evidenced by the growing number of clinical studies. To date, more than 100 trials have been performed or are currently ongoing to evaluate the effect of DC vaccines in a wide variety of disease states, with a main focus on the treatment of cancer .
While CD34+ bone marrow progenitor cells and circulating blood myeloid DCs have been applied as DC precursors in some clinical studies, the vast majority of DCs used for vaccination purposes are derived from autologous peripheral blood monocytes . The classic strategy for the ex vivo generation of monocyte-derived DCs consists of a two-step culture protocol, in which monocytes are differentiated towards immature DCs, followed by the induction of DC maturation. The total in vitro culture duration lasts one week, 5-6 days for DC differentiation and 1-2 days for subsequent DC maturation [5, 9, 10]. However, there is an increasing body of evidence that mature monocyte-derived DCs can be generated even after short-term cell culture for 2-3 days [9, 11–15]. As compared to the traditional 7-day approach, rapid expansion of DCs is associated with several advantages; it simplifies the laborious and time-consuming process of DC manufacturing and it reduces the actual risk of microbial contamination related to in vitro culture [10, 15]. Moreover, short-term cultured DCs exhibit equal or superior functional DC characteristics compared to their conventional long-term counterparts [13, 14]. Previous work has already demonstrated the feasibility of short-term culture of monocyte-derived DCs differentiated in the presence of granulocyte macrophage colony-stimulating factor (GM-CSF) and IL-4 (IL-4 DCs) [12–16].
Alternative differentiation of monocyte-derived DCs using a combination of GM-CSF and IL-15 has recently gained increasing interest. Interleukin-15 is a pleiotropic cytokine that plays a pivotal role in the generation of antigen-specific CD8+ T lymphocytes [17–19], the induction of memory CD8+ T cell immunity  and natural killer (NK) cell activation . Interleukin-15 differentiated DCs (IL-15 DCs) have been previously described to exhibit a distinct Langerhans cell(LC)-like phenotype and to possess unique immunostimulatory properties [22, 23]. This was more recently supported by the demonstration that IL-15 DCs are endowed with a superior capacity to induce antigen-specific cellular immune responses in an in vitro melanoma tumor model [24, 25]. These promising results make IL-15 DCs a qualified candidate for application in DC-based tumor immunotherapy [4, 26].
In addition, the Toll-like receptor (TLR) signal transduction pathway has recently emerged as an attractive alternative for the induction of DC maturation [10, 27, 28]. Toll-like receptors recognize pathogen-derived signals, such as microbial constituents (viral or bacterial-derived proteins, RNA or DNA) [29, 30]. Monocyte-derived DCs are known to express a series of TLRs, either on their cell surface (TLR2, TLR4) or intracellularly (TLR3, TLR7, TLR8 and TLR 9) . Recent studies have suggested that DC maturation using TLR3 or TLR7/8 ligands in association with prostaglandin E2 (PGE2) results in the generation of DCs that, besides migratory properties, possess the desired capacity to produce Th1-polarizing cytokines such as IL-12p70 [31–33]. In the context of cancer immunotherapy, Th1 polarization is considered conditio sine qua non for the induction of anti-tumor cytotoxic immune responses. However, despite the discovery of TLR ligands as powerful DC maturation agents, a non-TLR ligand-based maturation cocktail is currently regarded as the 'gold standard' for the induction of DC maturation in clinical trials. This widely adopted maturation cocktail was first described by Jonuleit et al. and is composed of the pro-inflammatory cytokines tumor necrosis factor (TNF)-α, IL-1β, IL-6 and PGE2. Prostaglandin E2 is generally believed to be indispensable for potentiating the migratory potential of DCs [35, 36], but hampered IL-12p70 production is considered to be its main drawback [37–39].
In view of the consideration that short-term DC culture, differentiation with IL-15 and TLR-induced maturation are proposed as separate attractive strategies to optimize the immunogenicity of clinical DC vaccination, we sought to determine whether an integration of these approaches is feasible and results in the generation of potent immunostimulatory DCs. We therefore examined the effect of culture duration on IL-15 DC phenotype and function by comparing short-term and long-term culture protocols. In addition, we evaluated the effect of two different maturation procedures on IL-15 DCs, juxtaposing the traditional pro-inflammatory cytokine combination with a clinical grade available maturation cocktail that includes a TLR7/8 ligand (resiquimod; R-848).
Generation of immature DCs
Differentiation and maturation procedures used in the present study.
Dendritic cell differentiation
IL-4 differentiated dendritic cells(IL-4 DCs)
Gentaur, Brussels, Belgium
R&D Systems, Minneapolis, USA
IL-15 differentiated dendritic cells(IL-15 DCs)
Gentaur, Brussels, Belgium
Immunotools, Friesoythe, Germany
Dendritic cell maturation
cc-mDC(conventional maturation cocktail, according to Jonuleit et al. )
Biosource, Nivelles, Belgium
R&D Systems, Minneapolis, USA
Biosource, Nivelles, Belgium
Pfizer, Puurs, Belgium
TLR-mDC(TLR7/8 agonist-based maturation cocktail)
Alexis Biochemicals, San Diego, USA
Biosource, Nivelles, Belgium
Immunotools, Friesoythe, Germany
Pfizer, Puurs, Belgium
Induction of DC maturation
Two different maturation cocktails were used for the induction of DC maturation. The conventionally applied combination of pro-inflammatory cytokines, first described by Jonuleit et al., was compared with a TLR7/8 agonist-based maturation cocktail. Table 1 provides an overview of the composition of the different maturation cocktails used in this study (Table 1). The resultant mature DCs were harvested 24 hr after addition of the maturation agents.
Duration of in vitro culture
Short-term versus long-term culture protocols were performed in order to determine the effect of culture duration on IL-15 DC phenotype and function. Short-term DCs were cultured for two days and subsequently matured for another 24 hr. Likewise, the long-term DC culture protocol included a six-day period for the generation of immature DCs followed by one day to obtain complete maturation.
Flow cytometric immunophenotyping
Immunofluorescent staining of cell surface antigens was performed using a panel of fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated monoclonal antibodies (mAb): CD1a (FITC, clone HI149), CD14 (FITC, clone MϕP9), CD40 (PE, clone 5C3), CD56 (FITC, clone NCAM16.2), CD70 (PE, clone Ki-24), CD80 (PE, clone L307.4), CD83 (PE, clone HB15e), CD86 (FITC, 2331 [FUN-1]), CD207/Langerin (PE, clone DCGM4), CD209/DC-SIGN (FITC, clone DCN46) and CCR7 (PE, clone 150503). All monoclonal antibodies were purchased from BD Biosciences (Erembodegem, Belgium), except for CD83 mAb (Invitrogen; Camarillo, CA, USA), CD207 mAb (Beckman Coulter; Marseille, France), and CCR7 mAb (R&D Systems; Minneapolis, MN, USA). Corresponding species- and isotype-matched antibodies were used as controls. Propidium iodide (PI; Sigma-Aldrich) was included in the analysis to discriminate between viable and dead cells. Data acquisition was performed on a FACScan™ multiparametric flow cytometer (BD Biosciences).
FITC-dextran endocytosis assay
The mannose receptor-mediated endocytosis of FITC-labeled dextran particles (MW 40 kDa; Sigma-Aldrich) was determined by co-incubation of 0.4 × 106 immature DCs with 100 μg/mL FITC-dextran at 37°C. Parallel experiments were carried out at 4°C to determine the non-specific FITC-dextran uptake (negative controls). After 60 minutes, internalization of FITC-dextran was stopped by washing the cells twice with ice-cold phosphate-buffered saline (PBS; Gibco Invitrogen; Paisley, UK). The endocytic capacity was subsequently analyzed by flow cytometric quantitation of the specific FITC fluorescence signal intensity.
Transwell™ chemotaxis assay
Cytokine secretion profile
The cytokine secretion profile of the different DC subsets was assessed by a multiplex immunoassay (MIA). Briefly, mature DCs were harvested, extensively washed and resuspended in fresh DC culture medium (5.0 × 105 cells/mL), not containing any exogenous growth factor or cytokine. After 24 hr of incubation, culture supernatants were analyzed for the presence of 11 different pro-inflammatory and Th1/Th2-polarizing cytokines using a commercially available MIA kit (FlowCytomix human Th1/Th2 11plex kit, Bender Medsystems; Vienna, Austria), according to the manufacturer's instructions.
IL-12p70 ELISA following CD40 ligation ("signal-3 assay")
Human CD40 ligand (CD40L)-expressing mouse 3T3 fibroblasts (kindly provided by Dr K. Thielemans, Free University Brussels, Brussels, Belgium) were suspended in a 48-well culture plate at a concentration of 2.5 × 105 cells per well and incubated overnight at 37°C to allow stable reattachment on the bottom surface of the well. The next day, mature DCs were seeded on the 3T3 feeder cell layer at a density of 5.0 × 105 cells per well in a total volume of 1 mL fresh DC culture medium. After 24 hr of co-incubation at 37°C, supernatants were carefully collected and stored frozen at -20°C until further use. The production of bioactive IL-12p70 was next determined using a commercially available standard sandwich ELISA kit (eBioscience; San Diego, CA, USA).
Autologous T cell stimulation capacity
To assess their autologous T cell stimulation capacity, mature DCs were pulsed with a panel of 32 MHC class I-restricted antigen epitopes derived from cytomegalovirus, Epstein-Barr virus and influenza virus, designated to as CEF peptide pool. The CEF peptide pool was obtained through the NIH AIDS Research & Reference Reagent Program (Division of AIDS, NIAID, NIH; Germantown, MD, USA) and used at a total concentration of 1 μg/μL.
Peptide-pulsed DCs were subsequently co-incubated with autologous PBLs at a 1:10 ratio in RPMI supplemented with 1% human AB serum. By day 7 of coculture, PBLs were harvested and restimulated with the CEF peptide pool for an additional 6 hr. A peptide mixture composed of human papilloma virus (HPV) type 16 E7 peptides served as negative control. The HPV peptide pool consisted of nine HPV16 E7 18- to 20-mer peptides (each overlapping by 10 amino acids), spanning the full length of the HPV16 E7 protein (1 μg/μL; AC Scientific; Duluth, GA, USA). Antigen-specific interferon (IFN)-γ secretion following peptide stimulation was determined by ELISA (Peprotech; Rocky Hill, NJ, USA) as per the manufacturer's protocol.
For intracellular staining (ICS) of IFN-γ, PBLs (1 × 106) were harvested after coculture with autologous CEF-pulsed DCs and subjected to a similar antigen stimulation protocol. Brefeldin A (1 μL; GolgiPlug™, BD Biosciences) was added during the stimulation period in order to sequester IFN-γ intracellularly. After 6 hr, PBLs were washed with PBS containing 1% bovine serum albumin and 0.1% sodium azide. Prior to the fixation and permeabilization procedure, cell surface staining for CD8 (PE, clone SK1, BD Biosciences) and CD3 (PerCP, clone SK7; BD Biosciences) was performed as described above. Next, cells were fixated and permeabilized using BD FACS™ lysing solution (1×) and permeabilizing solution 2 (1×). Intracellular staining was performed using IFN-γ mAb (15 ng per 1 × 106 cells; FITC, clone B27, BD Biosciences). Cells were subsequently incubated overnight at 4°C prior to flow cytometric analysis.
mRNA electroporation of IL-15 DCs
DNA transcription templates encoding the enhanced green fluorescent protein (eGFP) and influenza virus M1 matrix protein were respectively derived from the pGEM4Z/EGFP/A64 (kindly provided by Dr. E. Gilboa, then at Duke University Medical Center, Durham, NC, USA) and pGEM4Z/M1/A64 (kindly provided by Dr. A. Steinkasserer, University of Erlangen, Erlangen, Germany) plasmid vectors, according to our previously described protocol . Subsequent in vitro transcription of mRNA was performed using a commercially available T7 polymerase-based transcription kit (Ambion; Austin, TX, USA), following the manufacturer's instructions.
Mature IL-15 DCs were harvested and washed twice in serum-free IMDM culture medium (Cambrex Bio Science; Verviers, Belgium) and Opti-MEM I medium (Gibco Invitrogen), respectively. Next, 1 × 106 DCs were resuspended in a total volume of 200 μL Opti-MEM I and transferred to a 4.0-mm electroporation cuvette (Cell Projects; Harrietsham, UK). After addition of in vitro transcribed eGFP mRNA (20 μg) or M1 mRNA (10 μg), electroporation was performed using a Gene Pulser Xcell™ device (Bio-Rad Laboratories; Hercules, CA, USA) at predefined settings (300 V; 150 μF; 7.0 ms). The mRNA electroporation efficiency was assessed by flow cytometric analysis of the eGFP expression levels at different time points post-electroporation (4 hr, 24 hr, 48 hr). Propidium iodide was included in the assay to determine the post-electroporation cell viability.
Antigen-presenting function of mRNA-electroporated IL-15 DCs
HLA-A*0201+ IL-15 DCs were electroporated with M1-encoding mRNA and cocultured at a 1:10 ratio with autologous PBLs in 24-well polystyrene culture plates. Six days after initiation of the coculture experiments, PBLs were harvested and counted using an automatic hemocytometer.
To determine the presence of M1-specific CD8+ T lymphocytes, 1 × 106 PBLs were stained with anti-CD8 (FITC, clone SK1; BD Biosciences) and PE-conjugated HLA-A*0201 tetramer loaded with the influenza virus M1 matrix peptide (GILGFVFTL; kindly provided by Prof. P. Van der Bruggen, Ludwig Institute for Cancer Research, Brussels, Belgium). A dump channel (PerCP) was included to enhance the specificity of the tetramer assay.
Concomitantly, a fraction of the cocultured PBLs was subjected to antigen restimulation using two HLA-A*0201 restricted, virus-specific epitopes: the influenza matrix protein M1 peptide (M158-66 [GILGFVFTL]; Eurogentec; Seraing, Belgium) and an irrelevant peptide fragment derived from carcinoembryonic antigen (CEA571-579 [YLSGANLNL]; Eurogentec). Both peptides were used at a final concentration of 1 μg/mL. The duration of antigen stimulation was 4 hours, after which the level of IFN-γ producing CD8+ T cells was determined using a similar ICS protocol as described above.
Data mining and statistical analysis
Flow cytometric data analysis was performed using FlowJo version 8.4.4 (TreeStar; San Carlos, CA). Phenotypic results were expressed as Δ mean fluorescence intensity (MFI), i.e. the difference between the MFI values obtained from the specific mAb and the corresponding isotype-matched control, or calculated as a percentage of positive cells using the SuperEnhanced D-max or Overton histogram subtraction methods. GraphPad Prism 4.0 software (GraphPad Software; San Diego, CA, USA) was used for graphical data representations and statistical computations. Statistical analysis was performed using Student's t-test or repeated-measures ANOVA with Bonferroni's post-hoc testing, where appropriate. Any P-value < 0.05 was considered statistically significant.
Immature IL-15 DCs display a unique phenotype
TLR7/8-activated IL-15 DCs acquire a mature phenotype
Divergent phenotypic results were obtained with the 2 protocols used for the induction of IL-15 DC maturation: (i) a classic combination of pro-inflammatory cytokines (cc-mDC) versus (ii) a TLR7/8 ligand-containing maturation cocktail (TLR-mDC). As shown in Figure 2, the costimulatory molecules CD70, CD80 and CD86 were expressed at consistently higher levels upon activation of IL-15 DCs with the TLR7/8 agonist-based cocktail (TLR-mDC) as opposed to the conventional cytokine cocktail (cc-mDC). Moreover, a more profound maturation state was reached in TLR7/8-matured IL-15 DCs. This was reflected by the increased surface expression of CD83. The low expression of costimulatory molecules and CD83 after maturation of IL-15 DCs with the cytokine cocktail (cc-mDC) sharply contrasted with the effects of this maturation cocktail on IL-4 DCs (Figure 2; Additional file 1).
We next examined the effect of culture duration on the phenotype of mature IL-15 DCs. No apparent differences were observed between short-term (Figure 2a) and long-term cultured IL-15 DCs (Figure 2b), with the exception of CD86 which was found to be more pronounced in short-term cultured IL-15 DCs. The cell surface expression level of CD83 was independent of the duration of DC culture, suggesting that an equal maturation level can be obtained after short-term culture of IL-15 DCs.
A detailed overview of the phenotypic characteristics of mature IL-15 DCs is provided in "Additional File 1".
Immature IL-15 DCs are capable of phagocytosis
Migratory potential of IL-15 DCs
The migratory properties of immature IL-15 DCs (iDC), conventionally matured IL-15 DCs (cc-mDC) and TLR7/8-matured IL-15 DCs (TLR-mDC) were compared by assessment of their CCR7 expression pattern and their in vitro migratory potential using a standard Transwell™ chemotaxis assay.
Cytokine secretion profile of IL-15 DCs
Cytokine secretion profile of mature DCs.
short-term IL-15 DCs
long-term IL-15 DCs
Typical T h 1-polarizing
0 ± 0
0 ± 0
0 ± 0
0 ± 0
0 ± 0
0 ± 0
3671 ± 394
0 ± 0
4510 ± 686
0 ± 0
0 ± 0
0 ± 0
0 ± 0
0 ± 0
0 ± 0
Typical T h 2-polarizing
0 ± 0
0 ± 0
0 ± 0
0 ± 0
0 ± 0
9 ± 5
6 ± 6
0 ± 0
0 ± 0
11 ± 6
0 ± 0
4 ± 4
0 ± 0
50 ± 50
0 ± 0
281 ± 124
1132 ± 551
1078 ± 268
4424 ± 1446
39 ± 16
0 ± 0
0 ± 0
0 ± 0
0 ± 0
0 ± 0
60 ± 55
0 ± 0
146 ± 64
55 ± 33
71 ± 45
1065 ± 102
8163 ± 3246
1660 ± 78
13391 ± 2732
793 ± 51
9914 ± 986
6109 ± 2468
3876 ± 483
2061 ± 109
9495 ± 2289
The cytokine profile of IL-15 DCs was further explored by analyzing the release of Th2-related cytokines. As shown in table 2, no relevant amounts of IL-4, IL-5 and IL-10 could be detected in the culture supernatants of IL-15 DCs and IL-4 DCs (Table 2).
Moreover, signalling through TLR7/8 (TLR-mDC) resulted in the induction of high levels of TNF-α and IL-6 (Table 2). The production of the latter cytokine was substantially more pronounced in TLR-mDC as compared to cc-mDC. No statistically significant differences were found between short-term and long-term cultured TLR7/8-activated IL-15 DCs regarding their capacity to produce pro-inflammatory cytokines.
Efficient induction of viral antigen-specific CD8+ T cell responses by IL-15 DCs
We first examined whether the type of DC maturation cocktail (cc-mDC vs. TLR-mDC) had an impact on the capacity of IL-15 DCs to stimulate viral antigen-specific T cells. As shown in figure 6, a potent induction of antigen-specific CD8+ T cell responses was observed when IL-15 DCs were exposed to the TLR7/8 ligand-based maturation cocktail (TLR-mDC). By contrast, restimulation of PBLs after prior coculture with conventionally matured IL-15 DCs (cc-mDC) resulted in much lower levels of secreted IFN-γ, as determined by ELISA (Figure 6a; short-term TLR-mDC vs. cc-mDC, P < 0.001; long-term TLR-mDC vs. cc-mDC, P = 0.004). This trend was also reflected by our ICS experiments, although the difference in number of IFN-γ+ CD8+ T cells between both maturation cocktails did not reach statistiscal significance (Figure 6b; short-term TLR-mDC vs. cc-mDC, P = 0.07; long-term TLR-mDC vs. cc-mDC, P = 0.06).
We next determined the effect of culture duration on the induction of antigen-specific CD8+ T cell responses by IL-15 DCs. Short-term IL-15 DCs showed a distinctive superiority over their long-term cultured counterparts, regardless of the maturation cocktail used. This was evidenced by the increased ability of PBLs, stimulated by short-term cultured CEF-pulsed IL-15 DCs, to secrete IFN-γ upon antigen rechallenge. As shown in figure 6a, the antigen-specific IFN-γ release after CEF-restimulation of PBLs, was markedly increased in the short-term IL-15 DC subset. This phenomenon was found to be irrespective of the maturation protocol used (Figure 6a; short-term vs. long-term cc-mDC, P = 0.01; short-term vs. long-term TLR-mDC, P = 0.006). A parallel trend was observed in the number of IFN-γ+ CD8+ T cells (Figure 6b).
In general, a potent ability to induce recall immune responses could be attributed to short-term TLR7/8-matured IL-15 DCs. The superior T cell stimulation capacity of this DC subset was next verified against standard mature IL-4 DCs, and confirmed by the enhanced antigen-specific IFN-γ release and the higher frequencies of IFN-γ+ CD8+ T cells (Figure 6).
mRNA electroporation is an effective strategy for antigen loading of IL-15 DCs
The current standard to generate DCs for use in clinical trials consists of a one-week, two-step culture protocol in which monocyte-derived DCs are first differentiated in the presence of GM-CSF and IL-4, and subsequently matured with a combination of pro-inflammatory cytokines [8, 34]. In the present study, we established a novel protocol for the generation of monocyte-derived DCs by implementing the following modifications: (1) short-term culture for 2-3 days instead of 7 days, (2) alternative differentiation in the presence of GM-CSF and IL-15 (IL-15 DCs) and (3) alternative maturation induction through engagement of the TLR7/8 signalling pathway.
The modified protocol described here proved feasible for rapidly generating stimulatory and migratory DCs without any detrimental effects on cell viability and function. Neither differentiation with IL-15 nor TLR7/8 triggering had a negative influence on cell viability (data not shown). IL-15 DCs displayed a typical DC morphology already after 2-3 days of in vitro culture. As compared to standard IL-4 DCs, however, we observed that IL-15 DCs still retained some CD14 on their cell surface which, together with the lower expression levels of CD1a and CD209 (DC-SIGN), points to a less differentiated DC phenotype. This observation seemed unrelated to the duration of IL-15 DC culture, since long-term cultured IL-15 DCs expressed even higher levels of CD14 as compared to their short-term cultured counterparts. Previous studies have shown that replacement of IL-4 by IL-15 switches the differentiation of monocytes from 'genuine' monocyte-derived DCs to cells with a complex LC-like phenotype [22, 23, 40, 41]. This finding has fuelled the interest in alternative differentiation of monocyte-derived DCs by IL-15, since LC-like DCs have been advocated as ideal cellular vaccine vehicles in view of their potent antigen-presenting capacity [4, 42]. In the present study, we confirmed the Langerin (CD207)-positivity of IL-15 DCs [22, 23] and showed that CD207 upregulation is already maximal after short-term culture.
Another intriguing phenotypic finding was that a fraction of IL-15 DCs expresses CD56, a marker with predominant expression on natural killer (NK) and NK-T cells . In this regard, IL-15 DCs bear phenotypic similarity with monocyte-derived DCs generated in the presence of GM-CSF and IFN-γ (IFN-DCs). A subset of IFN-DCs was recently identified as being CD56-positive and endowed with endogenous cytotoxic activity, mediated by TNF-α-related apoptosis-inducing ligand (TRAIL) [43–45]. It is not completely speculative to draw a parallel between these IFN-DCs and IL-15 DCs, since there is evidence that type I interferons regulate IL-15 expression, suggesting a close relationship between both cytokines. In view of these data, it might be of particular interest to further elaborate on the phenotypic and potential functional resemblance of IFN-DCs and IL-15 DCs.
While it induces full phenotypic maturation in conventional IL-4 DCs, we observed that IL-15 DCs exhibit a suboptimal phenotype upon maturation induction with the widely adopted pro-inflammatory cytokine cocktail (cc-mDC). This was exemplified by the lower expression levels of the DC maturation marker CD83 and of vital costimulatory molecules such as CD80 and CD86. These phenotypic differences indicate that the results obtained with the classic maturation cocktail in IL-4 DCs cannot necessarily be extrapolated to IL-15 DCs.
Upon TLR activation, however, IL-15 DCs undergo an efficient maturation program and reach acceptable levels of CD83, CD70, CD80 and CD86; their phenotype appears close to that of fully mature IL-4 DCs, despite a distinct expression of CD83. The functional relevance of CD70 expression on the cell surface of TLR7/8-matured IL-15 DCs should be stressed, since CD70+ DCs favour Th1 immunity via the CD70-CD27 signalling pathway in an IL-12p70-independent fashion .
We next examined several functional endpoints to which IL-15 DCs must conform in order to be a valid immunotherapeutic vaccine candidate. Migration of DCs to secondary lymphoid organs is generally considered a conditio sine qua non for the success of DC-based immunotherapy . The migratory potential of IL-15 DCs has been sparsely investigated until present, with only one prior report demonstrating their migratory responsiveness to the CCR6 ligand CCL20 . However, acquisition of CCR7 upon maturation is one of the critical factors involved in effective DC migration to the draining lymph nodes [6, 48, 49].
As expected, immature DCs showed absent expression of CCR7 and correspondingly failed to migrate in the direction of CCL21 in a standard Transwell™ migration assay, hence validating our experimental set-up . While the classical combination of pro-inflammatory cytokines induces a migratory phenotype in standard IL-4 DCs (this study and [36, 50]), IL-15 DCs are found to be refractory to this maturation cocktail. The low CCR7 expression and concomitant weak migratory potential of conventionally matured IL-15 DCs could be, at least in part, explained by their less mature phenotype, as reflected by the relative low expression of CD83. In contrast, TLR7/8 agonist-matured IL-15 DCs are capable of effective CCR7-mediated migration. This result is in line with recent studies, showing that the addition of PGE2 to the maturation protocol reinstates the migratory program affected by TLR signalling [32, 33]. Our results clearly point to a superior migratory potential of short-term cultured TLR7/8-activated IL-15 DCs, which combine CCR7 expression with a migratory activity close to that of standard mature IL-4 DCs.
Besides possessing strong migratory properties, production of Th1-polarizing and pro-inflammatory cytokines is considered to be another characteristic of immunostimulatory DCs. Dendritic cell-mediated production of IL-12p70 upon T cell encounter in the lymph nodes is regarded as a decision step in the induction of a desired Th1 immune response . Absent IL-12p70 release is a major barrier to effective immunotherapy, which could be circumvented by modifying the current in vitro DC maturation protocol [32, 51]. As mentioned previously, the combination of TNF-α, IL-1β, IL-6 and PGE2 has been implemented as the standard maturation cocktail in most DC vaccine trials, despite its well-known drawback of hampering IL-12p70 production [38, 39]. Analogous to conventional IL-4 DCs, we observed no overt IL-12p70 release by IL-15 DCs matured with the pro-inflammatory cytokine cocktail. Conversely, TLR7/8-activated IL-15 DCs are able to produce detectable amounts of IL-12p70 after mimicking in vivo T cell encounter with CD40L-expressing fibroblasts. It should be noted that typical high IL-12p70 levels could not be attained after activation of the TLR7/8 pathway in IL-15 DCs. This may be due to an intrinsic inability of IL-15 DCs to produce IL-12, as had been previously suggested . The inclusion of PGE2 in our maturation cocktail provides another possible explanation. In contrast to recent studies [32, 33], we found that exposure to PGE2clearly suppresses the IL-12p70 release by TLR7/8-matured IL-15 DCs (data not shown). However, the physiological relevance of this limited IL-12p70 production capacity is questionable for several reasons. First and foremost, it has been suggested that even minor amounts of IL-12p70 have a Th1-skewing influence on the immune response [52, 53]. Thus one can hypothesize that the qualitative aspects (presence or absence of IL-12p70) are far more important than the quantitative. Within this context, it is also difficult to judge the significance of the more pronounced IL-12p70 release by long-term cultured TLR7/8-matured IL-15 DCs as opposed to their short-term counterparts. Secondly, IL-12p70 is an important but not exclusive signal for the induction of Th1 responses. Effective cellular immune responses can occur in the absence of functional IL-12p70, as has been exemplified in the case of Langerhans cells . Thirdly, we were able to show that TLR7/8-activated IL-15 DC preparations contain high amounts of IFN-γ, which are likely derived from expanded NK cells in the IL-15 DC cultures . A recent study by Hardy et al. has pointed out the pivotal role of contaminating IFN-γ producing NK cells in the induction of Th1 immunity by IL-15 DCs. As such, it might be speculated that NK cell-derived IFN-γ can partially replace IL-12p70 as a Th1-polarizing cytokine, thereby providing another mechanism by which IL-15 DCs can induce cellular immunity in an IL-12-independent fashion . Fourthly, TLR7/8-matured IL-15 DCs express CD70, which contributes to IL-12-independent Th1 differentiation as described above . Lastly, Dubsky et al. have recently elucidated that the enhanced potential of IL-15 DCs to induce cellular immune responses can be ascribed in part to membrane transpresentation of the Th1-polarizing cytokine IL-15 .
Efficient antigen presentation is another prerequisite that DCs must fulfill in order to be considered for implementation in DC-based immunotherapy protocols. Previous studies convincingly showed that IL-15 DCs are highly capable of inducing antigen-specific T cell responses in both viral and tumor antigen models [22, 24, 41]. It has been put forward that IL-15 DCs have an optimal antigen-presenting capacity; a recent study by Dubsky et al. has emphasized their potent ability to prime and expand high-avidity tumor antigen-specific CD8+ cytotoxic T lymphocytes . Our study extend these findings in several important respects. In the first place, activation of IL-15 DCs with a TLR7/8 stimulus appears to result in enhanced antigen-specific T cell responsiveness compared to maturation with a standard combination of pro-inflammatory cytokines. This observation should be interpreted together with the other effects of the two studied maturation cocktails on IL-15 DCs. On the basis of their phenotypic profile and their impaired ability for CCR7-driven migration and cytokine production, it can be hypothesized that IL-15 DCs are relatively inert to classical maturation stimuli, thereby providing an explanation for their inferior capacity to induce antigen-specific T cell responses. Since fully mature, immunostimulatory DCs are required for successful cancer immunotherapy, the clinical use of cytokine cocktail-matured IL-15 DCs cannot be recommended. Conversely, TLR7/8-matured IL-15 DCs showed a strong T cell stimulation capacity. This is particularly true for short-term cultured IL-15 DCs, which demonstrated a clear superiority over their long-term cultured counterparts and over conventional IL-4 DCs with regard to the induction of antigen-specific CD8+ T cell responses.
Taken together, short-term cultured and TLR7/8-matured IL-15 DCs best meet the imposed requirements to be recognized as immunostimulatory DCs. Not only do they possess an accurate phenotype as described above, they also combine strong migratory properties with some degree of IL-12p70 production and, most importantly, with a potent ability to promote antigen-specific T cell responses. Despite a more pronounced secondary production of IL-12p70, their long-term cultured counterparts behaved inferior with respect to migration and T cell stimulation capacity. In addition, reducing the time of DC culture facilitates the still arduous and costly process of ex vivo DC generation. Since short-term culture and TLR7/8-induced maturation of IL-15 DCs was considered as the "best-fit" approach to generate immunostimulatory DCs, the last part of our study was dedicated to the mRNA electroporability of this DC subset. Electroporation of mRNA is being increasingly applied in clinical vaccination trials as an elegant strategy for antigen loading of DCs [54, 55]. The attractiveness of this technique is based on the fact that it overcomes several drawbacks of other antigen delivery methods, such as the biosafety issues posed by viral gene delivery or the need for genome integration and the related risk of insertional mutagenesis associated with DNA transfection. In contrast to exogenous peptide pulsing, mRNA electroporation does not require prior knowledge of the HLA restriction characteristics of the antigen epitopes nor the need for HLA-matched donor DCs [55–57]. Here we demonstrate for the first time the mRNA transfectability of IL-15 DCs. Short-term cultured TLR7/8-matured IL-15 DCs show accurate transgene expression after eGFP mRNA electroporation, consistent with prior studies on TLR7/8-mediated DC maturation [31, 58]. Moreover, the observation that M1 mRNA-electroporated IL-15 DCs are capable to induce influenza matrix protein M1-specific T cells further proves the feasibility and applicability of this method.
In conclusion, we propose a novel approach for the generation of DCs, based on a combined strategy of (1) short-term culture of monocyte-derived DCs, (2) differentiation in the presence of IL-15 and (3) maturation using a TLR7/8 ligand-based cocktail. This integrative approach results in the generation of DCs that meet the phenotypic and functional endpoints for implementation in clinical vaccination trials.
List of Abbreviations
Conventional maturation cocktail (see Table 1 for details)
Cytomegalovirus, Epstein-Barr virus and influenza virus
Delta mean fluorescence intensity (MFI specific antibody - MFI isotype control)
Enhanced green fluorescent protein
Granulocyte macrophage colony-stimulating factor
Human leukocyte antigen
Human papilloma virus
Iscove's Modified Dulbecco's Medium
Major histocompatibility complex
Peripheral blood lymphocytes
Peripheral blood mononuclear cell(s)
peridinin chlorophyll protein
Roswell Park Memorial Institute
standard error of the mean
T helper type 1
TLR7/8 agonist-based maturation cocktail (see Table 1 for details)
Tumor necrosis factor.
This work was supported in part by research grants of the Fund for Scientific Research - Flanders (G.0370.08 and G.0082.08), the Foundation against Cancer (Stichting tegen Kanker), the Antwerp University Concerted Research Action (BOF-GOA, grant no. 802), the Methusalem financement program of the Flemish Government attributed to Dr Herman Goossens (Antwerp University, Vaccine & Infectious Disease Insitute, Vaxinfectio) and the Interuniversity Attraction Pole financement program (IAP #P6/41) of the Belgian Government. SA is a PhD fellow of the Fund for Scientific Research - Flanders (FWO - Vlaanderen). ELJMS was supported by a Stichting Emmanuel van der Schueren research grant of the Flemish League against Cancer (VLK). We thank Dr P. Ponsaerts (Antwerp University, Edegem, Belgium) for critical appraisal of the manuscript.
- Steinman RM, Cohn ZA: Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J Exp Med. 1974, 139: 380-397. 10.1084/jem.139.2.380.PubMed CentralView ArticlePubMedGoogle Scholar
- Steinman RM, Cohn ZA: Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. 1973, 137: 1142-1162. 10.1084/jem.137.5.1142.PubMed CentralView ArticlePubMedGoogle Scholar
- Steinman RM, Banchereau J: Taking dendritic cells into medicine. Nature. 2007, 449: 419-426. 10.1038/nature06175.View ArticlePubMedGoogle Scholar
- Palucka AK, Ueno H, Fay JW, Banchereau J: Taming cancer by inducing immunity via dendritic cells. Immunol Rev. 2007, 220: 129-150. 10.1111/j.1600-065X.2007.00575.x.View ArticlePubMedGoogle Scholar
- Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, Thielemans K, Bonehill A: Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother. 2007, 56: 1513-1537. 10.1007/s00262-007-0334-z.View ArticlePubMedGoogle Scholar
- Martin-Fontecha A, Lanzavecchia A, Sallusto F: Dendritic cell migration to peripheral lymph nodes. Handb Exp Pharmacol. 2009, 31-49. full_text.Google Scholar
- Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996, 2: 52-58. 10.1038/nm0196-52.View ArticlePubMedGoogle Scholar
- Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ: Dendritic cell immunotherapy: mapping the way. Nat Med. 2004, 10: 475-480. 10.1038/nm1039.View ArticlePubMedGoogle Scholar
- Ponsaerts P, Bosch Van den G, Cools N, Van Driessche A, Nijs G, Lenjou M, Lardon F, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF: Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. J Immunol. 2002, 169: 1669-1675.View ArticlePubMedGoogle Scholar
- Dauer M, Schnurr M, Eigler A: Dendritic cell-based cancer vaccination: quo vadis?. Expert Rev Vaccines. 2008, 7: 1041-1053. 10.1586/147605126.96.36.1991.View ArticlePubMedGoogle Scholar
- Czerniecki BJ, Carter C, Rivoltini L, Koski GK, Kim HI, Weng DE, Roros JG, Hijazi YM, Xu S, Rosenberg SA, Cohen PA: Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J Immunol. 1997, 159: 3823-3837.PubMedGoogle Scholar
- Dauer M, Obermaier B, Herten J, Haerle C, Pohl K, Rothenfusser S, Schnurr M, Endres S, Eigler A: Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol. 2003, 170: 4069-4076.View ArticlePubMedGoogle Scholar
- Dauer M, Schad K, Herten J, Junkmann J, Bauer C, Kiefl R, Endres S, Eigler A: FastDC derived from human monocytes within 48 h effectively prime tumor antigen-specific cytotoxic T cells. J Immunol Methods. 2005, 302: 145-155. 10.1016/j.jim.2005.05.010.View ArticlePubMedGoogle Scholar
- Tawab A, Fan Y, Read EJ, Kurlander RJ: Effect of ex vivo culture duration on phenotype and cytokine production by mature dendritic cells derived from peripheral blood monocytes. Transfusion. 2009, 49: 536-547. 10.1111/j.1537-2995.2008.02020.x.View ArticlePubMedGoogle Scholar
- Jarnjak-Jankovic S, Hammerstad H, Saeboe-Larssen S, Kvalheim G, Gaudernack G: A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines. BMC Cancer. 2007, 7: 119-10.1186/1471-2407-7-119.PubMed CentralView ArticlePubMedGoogle Scholar
- Tanaka F, Yamaguchi H, Haraguchi N, Mashino K, Ohta M, Inoue H, Mori M: Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes. Int J Oncol. 2006, 29: 1263-1268.PubMedGoogle Scholar
- Kanai T, Thomas EK, Yasutomi Y, Letvin NL: IL-15 stimulates the expansion of AIDS virus-specific CTL. J Immunol. 1996, 157: 3681-3687.PubMedGoogle Scholar
- Kuniyoshi JS, Kuniyoshi CJ, Lim AM, Wang FY, Bade ER, Lau R, Thomas EK, Weber JS: Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells. Cell Immunol. 1999, 193: 48-58. 10.1006/cimm.1999.1469.View ArticlePubMedGoogle Scholar
- Goddard RV, Prentice AG, Copplestone JA, Kaminski ER: In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids. Clin Exp Immunol. 2003, 131: 82-89. 10.1046/j.1365-2249.2003.02047.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Waldmann TA: The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006, 6: 595-601. 10.1038/nri1901.View ArticlePubMedGoogle Scholar
- Mortier E, Woo T, Advincula R, Gozalo S, Ma A: IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med. 2008, 205: 1213-1225. 10.1084/jem.20071913.PubMed CentralView ArticlePubMedGoogle Scholar
- Mohamadzadeh M, Berard F, Essert G, Chalouni C, Pulendran B, Davoust J, Bridges G, Palucka AK, Banchereau J: Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med. 2001, 194: 1013-1020. 10.1084/jem.194.7.1013.PubMed CentralView ArticlePubMedGoogle Scholar
- Feau S, Facchinetti V, Granucci F, Citterio S, Jarrossay D, Seresini S, Protti MP, Lanzavecchia A, Ricciardi-Castagnoli P: Dendritic cell-derived IL-2 production is regulated by IL-15 in humans and in mice. Blood. 2005, 105: 697-702. 10.1182/blood-2004-03-1059.View ArticlePubMedGoogle Scholar
- Dubsky P, Saito H, Leogier M, Dantin C, Connolly JE, Banchereau J, Palucka AK: IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol. 2007, 37: 1678-1690. 10.1002/eji.200636329.View ArticlePubMedGoogle Scholar
- Hardy MY, Kassianos AJ, Vulink A, Wilkinson R, Jongbloed SL, Hart DN, Radford KJ: NK cells enhance the induction of CTL responses by IL-15 monocyte-derived dendritic cells. Immunol Cell Biol. 2009, 87: 606-614. 10.1038/icb.2009.44.View ArticlePubMedGoogle Scholar
- Jacobs B, Wuttke M, Papewalis C, Seissler J, Schott M: Dendritic cell subtypes and in vitro generation of dendritic cells. Horm Metab Res. 2008, 40: 99-107. 10.1055/s-2007-1022561.View ArticlePubMedGoogle Scholar
- Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A: Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol. 2005, 6: 769-776. 10.1038/ni1223.PubMed CentralView ArticlePubMedGoogle Scholar
- Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, Schmid B, Schmitt E, Schild H, Radsak MP: Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood. 2006, 108: 544-550. 10.1182/blood-2005-10-4015.View ArticlePubMedGoogle Scholar
- Pulendran B: Tolls and beyond-many roads to vaccine immunity. N Engl J Med. 2007, 356: 1776-1778. 10.1056/NEJMcibr070454.View ArticlePubMedGoogle Scholar
- Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF: The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist. 2008, 13: 859-875. 10.1634/theoncologist.2008-0097.View ArticlePubMedGoogle Scholar
- Zobywalski A, Javorovic M, Frankenberger B, Pohla H, Kremmer E, Bigalke I, Schendel DJ: Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med. 2007, 5: 18-10.1186/1479-5876-5-18.PubMed CentralView ArticlePubMedGoogle Scholar
- Boullart AC, Aarntzen EH, Verdijk P, Jacobs JF, Schuurhuis DH, Benitez-Ribas D, Schreibelt G, Rakt van de MW, Scharenborg NM, de Boer A: Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother. 2008, 57: 1589-1597. 10.1007/s00262-008-0489-2.PubMed CentralView ArticlePubMedGoogle Scholar
- Dauer M, Lam V, Arnold H, Junkmann J, Kiefl R, Bauer C, Schnurr M, Endres S, Eigler A: Combined use of toll-like receptor agonists and prostaglandin E(2) in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production. J Immunol Methods. 2008, 337: 97-105. 10.1016/j.jim.2008.07.003.View ArticlePubMedGoogle Scholar
- Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH: Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997, 27: 3135-3142. 10.1002/eji.1830271209.View ArticlePubMedGoogle Scholar
- Scandella E, Men Y, Gillessen S, Forster R, Groettrup M: Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood. 2002, 100: 1354-1361. 10.1182/blood-2001-11-0017.View ArticlePubMedGoogle Scholar
- Luft T, Jefford M, Luetjens P, Toy T, Hochrein H, Masterman KA, Maliszewski C, Shortman K, Cebon J, Maraskovsky E: Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood. 2002, 100: 1362-1372. 10.1182/blood-2001-12-0360.View ArticlePubMedGoogle Scholar
- Kalinski P, Schuitemaker JH, Hilkens CM, Kapsenberg ML: Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol. 1998, 161: 2804-2809.PubMedGoogle Scholar
- Kalinski P, Vieira PL, Schuitemaker JH, de Jong EC, Kapsenberg ML: Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood. 2001, 97: 3466-3469. 10.1182/blood.V97.11.3466.View ArticlePubMedGoogle Scholar
- Lehner M, Morhart P, Stilper A, Petermann D, Weller P, Stachel D, Holter W: Efficient chemokine-dependent migration and primary and secondary IL-12 secretion by human dendritic cells stimulated through Toll-like receptors. J Immunother. 2007, 30: 312-322. 10.1097/01.cji.0000211345.11707.46.View ArticlePubMedGoogle Scholar
- Saikh KU, Khan AS, Kissner T, Ulrich RG: IL-15-induced conversion of monocytes to mature dendritic cells. Clin Exp Immunol. 2001, 126: 447-455. 10.1046/j.1365-2249.2001.01672.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Pulendran B, Dillon S, Joseph C, Curiel T, Banchereau J, Mohamadzadeh M: Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responses in vivo. Eur J Immunol. 2004, 34: 66-73. 10.1002/eji.200324567.View ArticlePubMedGoogle Scholar
- Santegoets SJ, Bontkes HJ, Stam AG, Bhoelan F, Ruizendaal JJ, Eertwegh van den AJ, Hooijberg E, Scheper RJ, de Gruijl TD: Inducing antitumor T cell immunity: comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model. J Immunol. 2008, 180: 4540-4549.View ArticlePubMedGoogle Scholar
- Papewalis C, Jacobs B, Wuttke M, Ullrich E, Baehring T, Fenk R, Willenberg HS, Schinner S, Cohnen M, Seissler J: IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo. J Immunol. 2008, 180: 1462-1470.View ArticlePubMedGoogle Scholar
- Korthals M, Safaian N, Kronenwett R, Maihofer D, Schott M, Papewalis C, Diaz Blanco E, Winter M, Czibere A, Haas R: Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. J Transl Med. 2007, 5: 46-10.1186/1479-5876-5-46.PubMed CentralView ArticlePubMedGoogle Scholar
- Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F: Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med. 2000, 191: 1777-1788. 10.1084/jem.191.10.1777.PubMed CentralView ArticlePubMedGoogle Scholar
- Iwamoto S, Ishida M, Takahashi K, Takeda K, Miyazaki A: Lipopolysaccharide stimulation converts vigorously washed dendritic cells (DCs) to nonexhausted DCs expressing CD70 and evoking long-lasting type 1 T cell responses. J Leukoc Biol. 2005, 78: 383-392. 10.1189/jlb.1104654.View ArticlePubMedGoogle Scholar
- Verdijk P, Aarntzen EH, Punt CJ, de Vries IJ, Figdor CG: Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin Biol Ther. 2008, 8: 865-874. 10.1517/147125188.8.131.525.View ArticlePubMedGoogle Scholar
- Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Ait-Yahia S, Briere F, Zlotnik A, Lebecque S, Caux C: Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med. 1998, 188: 373-386. 10.1084/jem.188.2.373.PubMed CentralView ArticlePubMedGoogle Scholar
- Cyster JG: Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med. 1999, 189: 447-450. 10.1084/jem.189.3.447.PubMed CentralView ArticlePubMedGoogle Scholar
- Ten Brinke A, Karsten ML, Dieker MC, Zwaginga JJ, van Ham SM: The clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization. Vaccine. 2007, 25: 7145-7152. 10.1016/j.vaccine.2007.07.031.View ArticlePubMedGoogle Scholar
- Bontkes HJ, Kramer D, Ruizendaal JJ, Kueter EW, van Tendeloo VF, Meijer CJ, Hooijberg E: Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther. 2007, 14: 366-375. 10.1038/sj.gt.3302874.View ArticlePubMedGoogle Scholar
- Park AY, Hondowicz BD, Scott P: IL-12 is required to maintain a Th1 response during Leishmania major infection. J Immunol. 2000, 165: 896-902.View ArticlePubMedGoogle Scholar
- Jongmans W, Tiemessen DM, van Vlodrop IJ, Mulders PF, Oosterwijk E: Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J Immunother. 2005, 28: 480-487. 10.1097/01.cji.0000171290.78495.66.View ArticlePubMedGoogle Scholar
- Van Tendeloo VF, Ponsaerts P, Berneman ZN: mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther. 2007, 9: 423-431.PubMedGoogle Scholar
- Smits EL, Anguille S, Cools N, Berneman ZN, Van Tendeloo VF: Dendritic cell-based cancer gene therapy. Hum Gene Ther. 2009, 20: 1106-1118. 10.1089/hum.2009.145.View ArticlePubMedGoogle Scholar
- Ponsaerts P, Van Tendeloo VF, Berneman ZN: Cancer immunotherapy using RNA-loaded dendritic cells. Clin Exp Immunol. 2003, 134: 378-384. 10.1046/j.1365-2249.2003.02286.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Van Driessche A, Ponsaerts P, Van Bockstaele DR, Van Tendeloo VF, Berneman ZN: Messenger RNA electroporation: an efficient tool in immunotherapy and stem cell research. Folia Histochem Cytobiol. 2005, 43: 213-216.PubMedGoogle Scholar
- Schuurhuis DH, Lesterhuis WJ, Kramer M, Looman MG, van Hout-Kuijer M, Schreibelt G, Boullart AC, Aarntzen EH, Benitez-Ribas D, Figdor CG: Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells. Cancer Immunol Immunother. 2009, 58: 1109-1115. 10.1007/s00262-008-0626-y.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.